231 related articles for article (PubMed ID: 29939178)
1. A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation.
Shankara Narayanan JS; Ray P; Naqvi I; White R
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29939178
[TBL] [Abstract][Full Text] [Related]
2. Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma.
Woeste MR; Shrestha R; Geller AE; Li S; Montoya-Durango D; Ding C; Hu X; Li H; Puckett A; Mitchell RA; Hayat T; Tan M; Li Y; McMasters KM; Martin RCG; Yan J
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072351
[TBL] [Abstract][Full Text] [Related]
3. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model.
Narayanan JSS; Ray P; Hayashi T; Whisenant TC; Vicente D; Carson DA; Miller AM; Schoenberger SP; White RR
Cancer Immunol Res; 2019 Oct; 7(10):1714-1726. PubMed ID: 31409607
[TBL] [Abstract][Full Text] [Related]
4. Irreversible Electroporation for Locally Advanced Pancreatic Cancer.
Timmer FEF; Geboers B; Ruarus AH; Schouten EAC; Nieuwenhuizen S; Puijk RS; de Vries JJJ; Meijerink MR; Scheffer HJ
Tech Vasc Interv Radiol; 2020 Jun; 23(2):100675. PubMed ID: 32591191
[TBL] [Abstract][Full Text] [Related]
5. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer.
Zhao J; Wen X; Tian L; Li T; Xu C; Wen X; Melancon MP; Gupta S; Shen B; Peng W; Li C
Nat Commun; 2019 Feb; 10(1):899. PubMed ID: 30796212
[TBL] [Abstract][Full Text] [Related]
6. Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model.
Bulvik BE; Rozenblum N; Gourevich S; Ahmed M; Andriyanov AV; Galun E; Goldberg SN
Radiology; 2016 Aug; 280(2):413-24. PubMed ID: 27429143
[TBL] [Abstract][Full Text] [Related]
7. Irreversible electroporation of pancreatic adenocarcinoma: a primer for the radiologist.
Rashid MF; Hecht EM; Steinman JA; Kluger MD
Abdom Radiol (NY); 2018 Feb; 43(2):457-466. PubMed ID: 29051982
[TBL] [Abstract][Full Text] [Related]
8. Role of local ablative techniques (Radiofrequency ablation and Irreversible Electroporation) in the treatment of pancreatic cancer.
Paiella S; Salvia R; Girelli R; Frigerio I; Giardino A; D'Onofrio M; De Marchi G; Bassi C
Updates Surg; 2016 Sep; 68(3):307-311. PubMed ID: 27535401
[TBL] [Abstract][Full Text] [Related]
9. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.
Martin RC; McFarland K; Ellis S; Velanovich V
J Am Coll Surg; 2012 Sep; 215(3):361-9. PubMed ID: 22726894
[TBL] [Abstract][Full Text] [Related]
10. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
Martin RC; Kwon D; Chalikonda S; Sellers M; Kotz E; Scoggins C; McMasters KM; Watkins K
Ann Surg; 2015 Sep; 262(3):486-94; discussion 492-4. PubMed ID: 26258317
[TBL] [Abstract][Full Text] [Related]
11. Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility.
Flak RV; Stender MT; Jensen TM; Andersen KL; Henriksen SD; Mortensen PB; Sall M; Thorlacius-Ussing O
Scand J Gastroenterol; 2019 Feb; 54(2):252-258. PubMed ID: 30907286
[TBL] [Abstract][Full Text] [Related]
12. [Irreversible electroporation in the treatment of locally advanced pancreatic cancer].
Záruba P; Hoskovec D; Lacman J; Hořejš J; Krška Z; Ryska M
Rozhl Chir; 2015 Dec; 94(12):504-9. PubMed ID: 26767900
[TBL] [Abstract][Full Text] [Related]
13. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models.
José A; Sobrevals L; Ivorra A; Fillat C
Cancer Lett; 2012 Apr; 317(1):16-23. PubMed ID: 22079741
[TBL] [Abstract][Full Text] [Related]
14. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy.
Ansari D; Kristoffersson S; Andersson R; Bergenfeldt M
Scand J Gastroenterol; 2017 Nov; 52(11):1165-1171. PubMed ID: 28687047
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model.
Shankara Narayanan JS; Hayashi T; Erdem S; McArdle S; Tiriac H; Ray P; Pu M; Mikulski Z; Miller A; Messer K; Carson D; Schoenberger S; White RR
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634919
[TBL] [Abstract][Full Text] [Related]
16. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy.
Månsson C; Brahmstaedt R; Nilsson A; Nygren P; Karlson BM
Eur J Surg Oncol; 2016 Sep; 42(9):1401-6. PubMed ID: 26906114
[TBL] [Abstract][Full Text] [Related]
17. Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer.
Yang J; Eresen A; Shangguan J; Ma Q; Yaghmai V; Zhang Z
Oncoimmunology; 2021 Feb; 10(1):1875638. PubMed ID: 33643692
[TBL] [Abstract][Full Text] [Related]
18. Irreversible electroporation promotes a pro-inflammatory tumor microenvironment and anti-tumor immunity in a mouse pancreatic cancer model.
Imran KM; Brock RM; Beitel-White N; Powar M; Orr K; Aycock KN; Alinezhadbalalami N; Salameh ZS; Eversole P; Tintera B; Markov Madanick J; Hendricks-Wenger A; Coutermarsh-Ott S; Davalos RV; Allen IC
Front Immunol; 2024; 15():1352821. PubMed ID: 38711517
[TBL] [Abstract][Full Text] [Related]
19. Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers?
Wu LM; Zhang LL; Chen XH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):117-124. PubMed ID: 30655073
[TBL] [Abstract][Full Text] [Related]
20. Irreversible electroporation in locally advanced pancreatic cancer.
Polyakov AN; Patyutko YI; Kudashkin NE; Kantieva DM; Romanova KA; Nasonova EA; Korshak AV; Egenov OA; Podluzhnyi DV
Khirurgiia (Mosk); 2023; (10):29-38. PubMed ID: 37916555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
